InsiderClue
← All stocks

Voyager Therapeutics, Inc.

VYGR Net selling
CIK 0001640266 #3912 in the set updated 17 Sep 2026
Bought (12 mo)
$0.00
out of their own pocket, the only kind of buying there is
Sold (12 mo)
$334.60K
$257.35K on a plan · $0.00 straight out of an exercise
Sold at will
$77.25K
3 of 12 sales
Net
−$334.60K
−$77.25K against sales at will

By person

7 insiders · 12 transactions
Insider
Role
Bought
Sold
Net
Holding
Of company
Worth
Change
Sandrock Alfred
President and CEO
—
$184.45K (4) scheduled
−$184.45K
472,549
0.7669%
$1.83M
+43.1%
Swartz Robin
COO & CBO
—
$55.29K (3) scheduled
−$55.29K
199,738
0.3242%
$772.99K
+68.1%
Jorgensen Nathan D.
Chief Financial Officer
—
$54.24K (2) scheduled
−$54.24K
151,416
0.2457%
$585.98K
—
Carter Todd Alfred
Chief Scientific Officer
—
$40.62K (3) scheduled
−$40.62K
145,718
0.2365%
$563.93K
+66.3%
Ferguson Toby
Chief Medical Officer
—
—
—
183,914
0.2985%
$711.75K
+75.2%
Fahey Sandell Jacquelyn
Chief Legal Officer
—
—
—
123,143
0.1998%
$476.56K
+33.9%
Shiferman Gregory L.
SVP and General Counsel
—
—
—
50,000
0.0811%
$193.50K
—

Individual transactions

3
Insider
Date
Role
Action
Shares
Price
Amount
Carter Todd Alfred
10 Feb 2026
Chief Scientific Officer
Sell
3,525
$3.85
$13.57K
Sandrock Alfred
10 Feb 2026
President and CEO
Sell
12,192
$3.78
$46.09K
Swartz Robin
10 Feb 2026
COO & CBO
Sell
4,569
$3.85
$17.59K
Show all 12 transactions →

What was left out

Form 4 filings counted 28
Amendments (4/A) skipped 0
Filings about a different issuer 0
Unreadable filings 0
Joint filings 0
Sales on a Rule 10b5-1 plan 9
Sales straight out of an exercise 0
Sales at will 3
Transactions with no price 0
Shares from compensation/vesting 291,500
History held since 21 Dec 2016